An observational study in Pancreatic Cancer, Microbiota and Cachexia, sponsored by Genton Graf Laurence. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by Genton Graf Laurence · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Pancreatic Neoplasms with a site in Switzerland — 9 open to participants now, 11 under way, 3 of them phase 3. Pancreatic Neoplasms · Switzerland.
Among the 58 studies in Pancreatic Neoplasms with a site in Switzerland, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2022, is one of 10 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 47th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →9 of the 58 studies in Pancreatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland, Germany
Ages 18+
Incyte Corporation · Sites in Switzerland, United States, Australia and 19 more countries
Ages 18+
Orion Corporation, Orion Pharma · Sites in Switzerland, United States, Denmark and 4 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in Switzerland, United States, Australia and 18 more countries
Ages 18+
Bayer · Sites in Switzerland, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 22 · Phase 3 10 · Phase 4 1
First in 1999; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 200 across 743 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 97 across the 47 interventional studies, 79 across the 10 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
Genton Graf Laurence is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Genton Graf Laurence has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Pancreatic Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.
Aim: Evaluating the effects of fecal microbiota transplantation (FMT) from 6 newly diagnosed cachectic and 6 non-cachectic pancreatic cancer patients, and 12 healthy age-and sex-matched volunteers on several cachexia-related parameters of 96 germ-free mice (4 per donor) over a 30-day period. The fecal material of all 12 pancreatic cancer patients will be collected at diagnosis before any cancer treatment onset.
Hypothesis: FMT of cachectic patients with pancreas cancer, naïve of any anti-cancer treatment and artificial nutrition, into germ-free mice impairs weight gain, in contrast to FMT of non-cachectic patients and healthy controls.
We will consider the fecal samples of 12 patients at diagnosis of pancreatic cancer including 6 patients with cachexia and 6 patients without cachexia, and therefore naïve of any anti-cancer treatment and artificial nutritional support. We will also include 12 healthy volunteers matched for gender and age (± 5 years) with the pancreatic cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with pancreatic cancer (n=12)
Cachectic pancreatic cancer patients (n=6)
Healthy matched subjects (n=12)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurements and sample collection at one timepoint.
Measurements and sample collection at one timepoint.
Measurements and sample collection at one timepoint.
Body weight changes in mice after fecal material transplantation.
Body weight (g)
Time frame: Between days 0 and 30
Differences in fecal microbiota
by 16S rRNA gene amplicon sequencing and functional profiles by metagenomic sequencing between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Body weight
in kilograms between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Waist-to-hip ratio
waist circumference (cm) and hip circumference (cm) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Fat mass
by bioelectrical impedance analysis (BIA) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Fat-free mass
by bioelectrical impedance analysis (BIA) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Muscle mass
surfaces of the paraspinal and abdominal wall muscles at the level of L3-L4 disk space by CT for pancreatic cancer patients
Time frame: at diagnosis
Nutritional intake
by 3-day food diary between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Resting energy expenditure (REE)
by indirect calorimetry between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by visual analogue scale ranging from 0 to 100 mm between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by fasting level of plasma ghrelin between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by fasting level of plasma leptin between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by fasting level of plasma glucagon-like peptide-1 (GLP-1) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by fasting level of plasma neuropeptide Y between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Appetite
by fasting level of plasma cholecystokinin between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Homeostatic model assessment (HOMA)-score
by fasting glycemia (mmol/l) and fasting insulinemia (mU/ml)) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Glycemia
by fasting glycemia (mmol/l) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Insulinemia
by fasting insulinemia (mU/ml) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Physical function
by handgrip strength between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Physical activity
by the International Physical Activity Questionnaire (IPAQ) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Quality of life
by the European Organisation for Research and Treatment of Cancer questionnaire (EORTC QLQ-C30) between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Mortality
by tumor progression between cachectic patients non-cachectic patients
Time frame: at diagnosis
Oral microbiota
by 16SrRNA gene amplicon sequencing and metagenomic sequencing between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Epithelial permeability
by fasting levels of plasma zonulin between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Epithelial permeability
by fasting levels of plasma lipopolysaccharide-binding protein between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Epithelial permeability
by fasting levels of plasma glucagon-like peptide-2 between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
GALT function and systemic inflammation
by fasting plasma level of C-reactive protein (CRP) and cytokines between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
GALT function and systemic inflammation
by peripheral blood T regulatory cells (Tregs) levels and phenotype between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
GALT function and systemic inflammation
by myeloid derived suppressor cells (MDSC) levels and phenotype between cachectic patients non-cachectic patients and healthy volunteers
Time frame: at diagnosis
Started Aug 2022 (actual). Primary completion is estimated for Apr 2025, 32 months after the start.
Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 32 months is below that.
Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genton Graf Laurence